Arthritis/rheumatic Disorders

Flu Vaccine Cuts Mortality in Rheumatoid Arthritis Patients

August 01, 2018

The researchers, after adjusting for potential confounding factors, found that RA patients who received the influenza vaccine had reduced risk of hospitalization for septicemia, bacteremia, or viremia.

Positive Phase 3 Results for Novel OA Pain Treatment Tanezumab

By July 18, 2018

The 16-week, double-blind, placebo-controlled, multicenter, parallel-group study included 698 patients who were randomized to 3 treatment groups: 2 doses of tanezumab 2.5mg; 1 dose of tanezumab 2.5mg followed by tanezumab 5mg, or 2 doses of placebo; each injection was administered once every 8 weeks.

Multiple Factors to Consider When Selecting NSAID for Arthritis

July 17, 2018

Although many NSAIDs must be taken every 4 hours, some come in long-acting or extended release forms. These can be taken as infrequently as once per day, which may be desirable for patients taking multiple medications.

Antibiotic-Methotrexate Combo Leads to Serious Side Effects in RA Patient

By June 25, 2018

The case involved a 68-year-old female patient with rheumatoid arthritis on methotrexate 10mg weekly who presented to the emergency department with complaints of lethargy and weakness after being prescribed a 2-week course of TS for a bacterial skin infection.

New Recommendations Guide Arthritis Pain Management

June 22, 2018

Patient-centered recommendations released by the European League Against Rheumatism

Cosentyx Slows Progression of Joint Structural Damage in Psoriatic Arthritis

By June 20, 2018

The update is based on data from the Phase 3 FUTURE 5 study (N=996) which evaluated Cosentyx versus placebo in patients with active psoriatic arthritis.

Many AKI Reports in FAERS Linked to Drugs Not Recognized as Nephrotoxic

By June 12, 2018

According to the authors, this is the first study to identify medications most commonly reported for a specific adverse reaction using this database.

Does Rheumatoid Arthritis Tx Improve Mental Health Outcomes?

June 06, 2018

When the analysis was limited to studies that examined bDMARDs vs no-treatment placebo controls, bDMARDs had a substantial benefit on physical health, measured by the Physical Component Summary, compared with mental health.

Treatment for Prosthetic Joint Infections Gets FDA's QIDP Designation

By June 04, 2018

PJI is a challenging complication of joint arthroplasty with few effective treatment options.

Rheumatoid Arthritis Treatment Olumiant Gets FDA Approval

By June 01, 2018

The approval was supported by a clinical program that included dose-ranging trials (Study I and II) and confirmatory Phase 3 trials (Study III and IV).

Consensi Approved to Treat Hypertension and Osteoarthritis Pain

By June 01, 2018

Consensi combines amlodipine besylate, a calcium-channel blocker (CCB), and celecoxib, a nonsteroidal anti-inflammatory drug (NSAID).

RA Treatment During Pregnancy: Is Infection Risk Greater in Offspring?

By May 18, 2018

Offspring were followed from birth until 12 months, first indication of serious infection, end of commercial insurance eligibility, death or end of study period, whichever came first.

Certolizumab Pegol Beneficial in Non-Radiographic Axial Spondyloarthritis

By May 17, 2018

During the 52-week trial period, the treatment group received a 400mg dose of CZP subcutaneously at weeks 0, 2, and 4, followed by 200mg of CZP every 2 weeks starting at week 6; or placebo.

Actemra SC Approved to Treat Rare Form of Juvenile Arthritis

By May 14, 2018

Approval of the SC formulation for this patient population was supported by data from the Phase 1b JIGSAW-117 trial, a 52-week, open-label multicenter, pharmacokinetic/pharmacodynamic bridging study (N=52) that aimed to determine the appropriate dosing regimen of Actemra SC based on body weight in children with PJIA.

Corticosteroid-Related Adverse Events Examined Based on Dose, Duration

By May 14, 2018

Using a privately-insured administrative database, researchers examined a total of 78,704 patients with autoimmune or inflammatory disease diagnoses between 2006 and 2015.

Anxiety Levels Tied to Bone Mineral Density Post-Menopause

May 14, 2018

There was a significant correlation for anxiety levels with age, menopausal age, years since menopause, and depressive symptoms; multiple regression analysis predicted reduced BMD in the lumbar spine.

Osteoporosis Drug Shows Cardioprotective Potential at 10-Year Follow-Up

By May 11, 2018

The 1-year cardiovascular mortality hazard ratio (HR) for alendronate users was 0.33 (95% CI, 0.17 to 0.65) and 0.55 for incident myocardial infarction (95% CI, 0.34 to 0.89).

Fx Risk Should Be Monitored in Bisphosphonate Drug Holiday

May 11, 2018

The researchers found that 15.4% of the patients developed a fracture during follow-up. Yearly fracture incidence varied from 3.7 to 9.9%, peaking during years four and five at 9.9 and 9.8%, respectively.

Provider Counseling for Weight Loss Up for Arthritis, Overweight

May 08, 2018

From 2002 to 2014, 10.4 percent increase in estimates of provider counseling for weight loss

HBV Reactivation Examined in Patients Treated With TNF Antagonists

By May 03, 2018

The authors examined data from 8887 individuals who began TNF antagonist treatment for an autoimmune disease from 2001 through 2010 and were followed through 2012; 52% of these patients were screened for HBV before treatment.

Severe Obesity Tied to Faster Progression to Disability With RA

May 01, 2018

The researchers found that at baseline, severely obese patients had higher disability scores versus overweight patients in both Forward and VARA.

Zilretta Benefits 'Real-World' Patients With Knee OA, Says Study

By April 26, 2018

Patients who received a repeat Zilretta injection experienced a 64% improvement in Western Ontario and McMaster Universities Arthritis Index (WOMAC)-A (pain), a 66% improvement in WOMAC-B (stiffness), a 64% improvement on WOMAC-C (function), and improvement represented by a doubling of the KOOS Quality of Life subscale score by Week 4.

FDA Advisory Committee Votes on Novel RA Treatment Baricitinib

By April 24, 2018

The panel's decision was based on four Phase 3 studies which evaluated the impact of baricitinib on RA signs and symptoms, physical function, joint damage progression and other patient-reported outcomes.

One in Four Adults Report Having Arthritis

April 24, 2018

The researchers found that the age-adjusted prevalence of arthritis was 24.7% (OA, 9.7%; RA, 4.2%; other arthritis, 2.8%). Over the study period the prevalence of OA increased from 6.6 to 14.3%, while RA prevalence decreased from 5.9 to 3.8%.

GI Safety Compared for NSAIDs in Patients With Arthritis

By April 19, 2018

The randomized, double-blind, controlled trial (N=24,081) included patients with rheumatoid arthritis or osteoarthritis who required chronic NSAID treatment.

Certain RA Treatments Tied to Improvements in Blood Pressure

By April 18, 2018

For this study, researchers used the Veterans Affairs electronic medical record databases to identify unique dispensing of methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, tumor necrosis factor inhibitors, and prednisone in order to assess the effect of these treatments on systolic and diastolic blood pressure (SBP and DBP), as well as incident hypertension among RA patients.

Untrimmed Toenails: A Marker of Functional Status in Older Patients?

By April 13, 2018

For older patients, toenail length can provide important insight into a patient's functional status.

Inhibiting mitochondrial responses after intra-articular fracture slows progression of posttraumatic osteoarthritis

April 13, 2018

Intra-articular fractures (IAFs) often lead to posttraumatic osteoarthritis (PTOA) through mechanisms that involve mitochondria.

Top-Line Results Announced for Investigational RA Treatment Upadacitinib

By April 09, 2018

At week 12, results showed 71% in the upadacitinib group had achieved ACR20, compared to 63% and 36% in the adalimumab and placebo groups, respectively.

Cimzia Label Update Provides New Information for Women of Childbearing Age

By March 22, 2018

Data added to the labeling includes first-of-their-kind pharmacokinetic studies demonstrating negligible to low transfer of CIMZIA through placenta and minimal transfer to breast milk from mother to infant.